Prostate-specific Membrane Antigen PET in Prostate Cancer
- PMID: 33787338
- DOI: 10.1148/radiol.2021202771
Prostate-specific Membrane Antigen PET in Prostate Cancer
Abstract
Prostate-specific membrane antigen (PSMA)-targeted radiopharmaceuticals are playing a large role at the time of initial staging and biochemical recurrence for localizing prostate cancer, as well as in other emerging clinical settings. PSMA PET has demonstrated increased detection rate compared with conventional imaging and has been shown to change management plans in a substantial percentage of cases. The aims of this narrative review are to highlight the development and clinical impact of PSMA PET radiopharmaceuticals, to compare PSMA to other agents such as fluorine 18 fluciclovine and carbon 11 choline, and to highlight some of the individual PSMA PET agents that have contributed to the advancement of prostate cancer imaging.
© RSNA, 2021 See also the editorial by Jadvar in this issue.
Comment in
-
Competitive Advantage of PSMA Theranostics in Prostate Cancer.Radiology. 2021 May;299(2):261-263. doi: 10.1148/radiol.2021210348. Epub 2021 Mar 30. Radiology. 2021. PMID: 33788590 Free PMC article. No abstract available.
-
Imaging.J Urol. 2021 Oct;206(4):1044. doi: 10.1097/JU.0000000000002131. Epub 2021 Jul 20. J Urol. 2021. PMID: 34281351 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous